[{"orgOrder":0,"company":"Bonafide Health","sponsor":"Pharmavite","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Bonafide Pollen","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bonafide Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bonafide Health \/ Pharmavite","highestDevelopmentStatusID":"12","companyTruncated":"Bonafide Health \/ Pharmavite"}]

Find Clinical Drug Pipeline Developments & Deals by Bonafide Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cosmoprof
                          Not Confirmed
                          Cosmoprof
                          Not Confirmed

                          Details : Through the acquisition, Pharmavite will expand its portfolio of women's health by including Relizen (bonafide pollen), a plant-based & hormone-free supplement, which is safe to use for menopause relief.

                          Brand Name : Relizen

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 30, 2023

                          Lead Product(s) : Bonafide Pollen

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved

                          Sponsor : Pharmavite

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank